|
Link found between
Biologic Treatments for Psoriasis and Cancer
Journal of the American Medical Association, May
2006
Objective of Study: To assess the extent to
which anti-TNF antibody therapies may increase the risk of serious infections
and malignancies.
Study Selection: 9 studies were reviewed that included randomized,
placebo-controlled trials of the 2-licensed anti-TNF antibodies (infliximab and
adalimumab (Humira) used for 12 weeks or more. 3493 patients had received
treatment and 1512 had received placebo.
Conclusions: There is evidence of increased risk of serious
infections and a dose-dependent increased risk of malignancies... treated with
anti-TNF antibody therapy. The formal meta-analysis with pooled sparse
adverse events data from randomized controlled trials serves as a tool to assess
harmful drug effects.
Analysis contributes to the findings that challenge the previously presumed
safety porfile of anti-TNF therapy.
Excerpted from:
Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of
Serious Infections and Malignancies. A Systematic Review and Meta-Analysis
of Rare and Harmful Effects in Randomized Controlled Trials. JAMA, Jounal of the American
Medical Association, May 17 2006 - Vol 295, No 19.
Authors: Tim Bongartz, MD; Alex J Sutton, PhD; Michael J Sweeting MSe;
Iain Buchan MD MFPH; Eric L Matteson MD MPH; and Victor Montori MD MSe
Read complete article
|
